- Title
- Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios
- Creator
- Saglio, Giuseppe; le Coutre, Philipp; Cortes, Jorge; Mayer, Jiří; Rowlings, Philip; Mahon, François-Xavier; Kroog, Glenn; Gooden, Kyna; Subar, Milayna; Shah, Neil P.
- Relation
- Annals of Hematology Vol. 96, Issue 8, p. 1303-1313
- Publisher Link
- http://dx.doi.org/10.1007/s00277-017-3012-z
- Publisher
- Springer
- Resource Type
- journal article
- Date
- 2017
- Description
- With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options. Cardiovascular ischemic event incidence in clinical trials was evaluated in 2712 dasatinib-treated patients with Philadelphia chromosome-positive (Ph+) leukemias from 11 first- and second-line trials (pooled), newly diagnosed CML patients treated with dasatinib or imatinib (DASISION), and prostate cancer patients treated with dasatinib or placebo plus docetaxel/prednisone (READY). Overall, 2-4% of dasatinib-treated patients had cardiovascular ischemic events. Most dasatinib-treated patients with an event had a history of and/or risk factor for atherosclerosis (pooled 77 with history/risk and event/96 with events; DASISION 8/10; READY 15/18). Most cardiovascular ischemic events occurred within 1 year of initiating dasatinib (pooled 69/96; DASISION 7/10; READY 16/18). Comparison of observed and expected event rates through standardized incidence ratios indicates that dasatinib does not increase risk for cardiovascular ischemic events compared with external reference populations.
- Subject
- chronic myeloid leukemia; tyrosine kinase inhibitors; dasatinib; cardiovascular; ischemic
- Identifier
- http://hdl.handle.net/1959.13/1352442
- Identifier
- uon:30888
- Identifier
- ISSN:0939-5555
- Rights
- This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Language
- eng
- Full Text
- Reviewed
- Hits: 6847
- Visitors: 7099
- Downloads: 302
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 539 KB | Adobe Acrobat PDF | View Details Download |